{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T16:17:00Z","timestamp":1791908220707,"version":"4.3.4"},"reference-count":24,"publisher":"Elsevier BV","issue":"7","license":[{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,10,28]],"date-time":"2025-10-28T00:00:00Z","timestamp":1761609600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100009947","name":"Merck Sharp and Dohme United Kingdom","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100009947","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004334","name":"Merck","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004334","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","onlinejcf.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Cardiac Failure"],"published-print":{"date-parts":[[2026,7]]},"DOI":"10.1016\/j.cardfail.2025.07.021","type":"journal-article","created":{"date-parts":[[2025,8,20]],"date-time":"2025-08-20T00:51:56Z","timestamp":1755651116000},"page":"1153-1161","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"title":["Characterizing real-world use of vericiguat in the United States"],"prefix":"10.1016","volume":"32","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4988-5594","authenticated-orcid":false,"given":"ALEJANDRO","family":"VICTORES","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6036-2498","authenticated-orcid":false,"given":"LORI D.","family":"BASH","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9620-1306","authenticated-orcid":false,"given":"BOSHU","family":"RU","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8452-2831","authenticated-orcid":false,"given":"ARIELLE","family":"MARKS-ANGLIN","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7269-6391","authenticated-orcid":false,"given":"CIARAN","family":"McMULLAN","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"ANDRA","family":"STEVENSON","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1807-3465","authenticated-orcid":false,"given":"ENGELS N.","family":"OBI","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3222-1719","authenticated-orcid":false,"given":"ROBERT J.","family":"MENTZ","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8338-1798","authenticated-orcid":false,"suffix":"JR.","given":"JAMES L.","family":"JANUZZI","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.cardfail.2025.07.021_bib0001","doi-asserted-by":"crossref","first-page":"e56","DOI":"10.1161\/CIR.0000000000000659","article-title":"Heart disease and stroke statistics\u20142019 update: a report from the American Heart Association","volume":"139","author":"Benjamin","year":"2019","journal-title":"Circulation"},{"key":"10.1016\/j.cardfail.2025.07.021_bib0002","doi-asserted-by":"crossref","first-page":"e139","DOI":"10.1161\/CIR.0000000000000757","article-title":"Heart Disease and Stroke Statistics\u20142020 update: a report from the American Heart Association","volume":"141","author":"Virani","year":"2020","journal-title":"Circulation"},{"key":"10.1016\/j.cardfail.2025.07.021_bib0003","doi-asserted-by":"crossref","first-page":"e263","DOI":"10.1016\/j.jacc.2021.12.012","article-title":"2022 AHA\/ACC\/HFSA guideline for the management of heart failure: a report of the American College of Cardiology\/American Heart Association Joint Committee on Clinical Practice Guidelines","volume":"79","author":"Heidenreich","year":"2022","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.cardfail.2025.07.021_bib0004","doi-asserted-by":"crossref","first-page":"4015","DOI":"10.1007\/s12325-020-01456-1","article-title":"Clinical and economic burden of chronic heart failure and reduced ejection fraction following a worsening heart failure event","volume":"37","author":"Butler","year":"2020","journal-title":"Adv Ther"},{"key":"10.1016\/j.cardfail.2025.07.021_bib0005","doi-asserted-by":"crossref","first-page":"809","DOI":"10.1016\/S0735-1097(20)31436-4","article-title":"Characteristics and outcomes of heart failure with reduced ejection fraction patients enrolled in Medicare advantage with and without recent worsening heart failure","volume":"75","author":"Mentz","year":"2020","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.cardfail.2025.07.021_bib0006","doi-asserted-by":"crossref","first-page":"935","DOI":"10.1016\/j.jacc.2018.11.049","article-title":"Clinical course of patients with worsening heart failure with reduced ejection fraction","volume":"73","author":"Butler","year":"2019","journal-title":"J Am Coll Cardiol"},{"issue":"Suppl 1","key":"10.1016\/j.cardfail.2025.07.021_bib0007","article-title":"Abstract 14596: Differences in healthcare resource utilization among patients receiving comprehensive guideline-directed medical therapy by prior history of worsening heart failure events","volume":"148","author":"Coyle","year":"2023","journal-title":"Circulation"},{"key":"10.1016\/j.cardfail.2025.07.021_bib0009","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1002\/ejhf.2333","volume":"24","author":"McDonagh","year":"2022","journal-title":"Eur J Heart Fail"},{"key":"10.1016\/j.cardfail.2025.07.021_bib0010","doi-asserted-by":"crossref","first-page":"3627","DOI":"10.1093\/eurheartj\/ehad195","article-title":"2023 focused update of the 2021 ESC guidelines for the diagnosis and treatment of acute and chronic heart failure","volume":"44","author":"McDonagh","year":"2023","journal-title":"Eur Heart J"},{"key":"10.1016\/j.cardfail.2025.07.021_bib0011","doi-asserted-by":"crossref","first-page":"294","DOI":"10.4070\/kcj.2023.0024","article-title":"Treatment strategies of improving quality of care in patients with heart failure","volume":"53","author":"Kim","year":"2023","journal-title":"Korean Circ J"},{"key":"10.1016\/j.cardfail.2025.07.021_bib0012","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1002\/ejhf.1351","article-title":"Medication dosing for heart failure with reduced ejection fraction\u2014opportunities and challenges","volume":"21","author":"Marti","year":"2019","journal-title":"Eur J Heart Fail"},{"key":"10.1016\/j.cardfail.2025.07.021_bib0013","doi-asserted-by":"crossref","first-page":"931","DOI":"10.1007\/s00228-024-03654-0","article-title":"Real-world characteristics and use patterns of patients treated with vericiguat: a nationwide longitudinal cohort study in Germany","volume":"80","author":"Kerwagen","year":"2024","journal-title":"Eur J Clin Pharmacol"},{"key":"10.1016\/j.cardfail.2025.07.021_bib0014","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3390\/jcm13113222","article-title":"Vericiguat use in patients with heart failure in real-world settings during the first year after the drug authorization in Japan","volume":"13","author":"Okami","year":"2024","journal-title":"J Clin Med"},{"key":"10.1016\/j.cardfail.2025.07.021_bib0015","doi-asserted-by":"crossref","first-page":"ooad035","DOI":"10.1093\/jamiaopen\/ooad035","article-title":"A global federated real-world data and analytics platform for research","volume":"6","author":"Palchuk","year":"2023","journal-title":"JAMIA Open"},{"issue":"Suppl","key":"10.1016\/j.cardfail.2025.07.021_bib0016","first-page":"27","article-title":"Factors associated with adherence to guideline-directed medical therapy (GDMT) among U.S. patients with heart failure with reduced ejection fraction (HFrEF)","volume":"83","author":"Morris","year":"2024","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.cardfail.2025.07.021_bib0017","doi-asserted-by":"crossref","first-page":"1365","DOI":"10.1016\/j.jchf.2024.03.001","article-title":"Eligibility and projected benefits of rapid initiation of quadruple therapy for newly diagnosed heart failure","volume":"12","author":"Greene","year":"2024","journal-title":"JACC Heart Fail"},{"key":"10.1016\/j.cardfail.2025.07.021_bib0018","doi-asserted-by":"crossref","first-page":"2251","DOI":"10.1001\/jama.2015.15734","article-title":"Effect of vericiguat, a soluble guanylate cyclase stimulator, on natriuretic peptide levels in patients with worsening chronic heart failure and reduced ejection fraction: the SOCRATES-REDUCED randomized trial","volume":"314","author":"Gheorghiade","year":"2015","journal-title":"JAMA"},{"key":"10.1016\/j.cardfail.2025.07.021_bib0019","doi-asserted-by":"crossref","first-page":"1883","DOI":"10.1056\/NEJMoa1915928","article-title":"Vericiguat in patients with heart failure and reduced ejection fraction","volume":"382","author":"Armstrong","year":"2020","journal-title":"N Engl J Med"},{"key":"10.1016\/j.cardfail.2025.07.021_bib0020","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.119.015042","article-title":"Real-world analysis of guideline-based therapy after hospitalization for heart failure","volume":"9","author":"Wirtz","year":"2020","journal-title":"J Am Heart Assoc"},{"key":"10.1016\/j.cardfail.2025.07.021_bib0021","doi-asserted-by":"crossref","first-page":"1359","DOI":"10.1007\/s10741-020-09979-z","article-title":"Clinical inertia in the treatment of heart failure: a major issue to tackle","volume":"26","author":"Verhestraeten","year":"2021","journal-title":"Heart Fail Rev"},{"key":"10.1016\/j.cardfail.2025.07.021_bib0022","doi-asserted-by":"crossref","first-page":"1759","DOI":"10.1002\/ejhf.1857","article-title":"Guideline-directed medical therapy for heart failure does not exist: a non-judgmental framework for describing the level of adherence to evidence-based drug treatments for patients with a reduced ejection fraction","volume":"22","author":"Packer","year":"2020","journal-title":"Eur J Heart Fail"},{"key":"10.1016\/j.cardfail.2025.07.021_bib0023","doi-asserted-by":"crossref","first-page":"2365","DOI":"10.1016\/j.jacc.2019.02.015","article-title":"Titration of medical therapy for heart failure with reduced ejection fraction","volume":"73","author":"Greene","year":"2019","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.cardfail.2025.07.021_bib0024","doi-asserted-by":"crossref","first-page":"554","DOI":"10.1016\/j.jchf.2024.08.017","article-title":"Efficacy, safety and mechanistic impact of a heart failure guideline-directed medical therapy clinic","volume":"13","author":"Spahillari","year":"2024","journal-title":"JACC Heart Fail"},{"key":"10.1016\/j.cardfail.2025.07.021_bib0025","doi-asserted-by":"crossref","first-page":"44","DOI":"10.36469\/jheor.2023.87538","article-title":"Use of open claims vs closed claims in health outcomes research","volume":"10","author":"Baser","year":"2023","journal-title":"J Health Econ Outcomes Res"}],"container-title":["Journal of Cardiac Failure"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1071916425003653?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1071916425003653?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,8,11]],"date-time":"2026-08-11T20:45:33Z","timestamp":1786481133000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1071916425003653"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7]]},"references-count":24,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2026,7]]}},"alternative-id":["S1071916425003653"],"URL":"https:\/\/doi.org\/10.1016\/j.cardfail.2025.07.021","relation":{},"ISSN":["1071-9164"],"issn-type":[{"value":"1071-9164","type":"print"}],"subject":[],"published":{"date-parts":[[2026,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Characterizing real-world use of vericiguat in the United States","name":"articletitle","label":"Article Title"},{"value":"Journal of Cardiac Failure","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.cardfail.2025.07.021","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Merck & Co., Inc., Rahway, NJ, USA and its affiliates and The Author(s). Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}